This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
by Zacks Equity Research
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
by Zacks Equity Research
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $67.26, moving +1.04% from the previous trading session.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Here's What is Driving Amgen (AMGN) Stock's Outperformance
by Zacks Equity Research
Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. It is also rapidly advancing its robust pipeline.
Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023?
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.
Astrazeneca (AZN) Stock Moves -0.56%: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $65.61, marking a -0.56% move from the previous day.
Astrazeneca (AZN) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
AstraZeneca (AZN) Stock Up 5% in a Year: What Awaits in 2023?
by Zacks Equity Research
AstraZeneca (AZN) expects total revenues to increase in the low-to-mid single-digit percentage in 2023 at CER.
Astrazeneca (AZN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $65.18, moving +1.54% from the previous trading session.
AstraZeneca (AZN) Posts Positive Data From Lung Cancer Studies
by Zacks Equity Research
Data from late-stage label expansion studies show that AstraZeneca's (AZN) cancer drugs are effective for treating non-small cell lung cancer indications.
Zacks Industry Outlook Highlights J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi
by Zacks Equity Research
J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi have been highlighted in this Industry Outlook article.
5 Large Drug Stocks to Watch as Sector Picks Up in 2023
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, J&J (JNJ), Novo Nordisk (NVO), AstraZeneca (AZN), Novartis (NVS), and Sanofi (SNY) are worth retaining in your portfolio.
AstraZeneca (AZN) Enhertu Betters Outcomes in Multi-Tumor Study
by Zacks Equity Research
AstraZeneca (AZN) and Daiichi Sankyo' Enhertu met the pre-specified criteria for objective response rate and duration of response in the DESTINY-PanTumor02 phase II study.
Emergent's (EBS) Q4 Earnings Miss, Sales Beat Estimates
by Zacks Equity Research
Emergent (EBS) reported mixed fourth-quarter 2022 results. While the company significantly misses the mark on earnings, it beat sales estimates.
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
Pharma Stock Roundup: FDA Updates for SNY, PFE & Others, EU Nod to AZN Cancer Combo
by Kinjel Shah
FDA approves Sanofi's (SNY) Altuviiio and grants a priority tag to Pfizer's (PFE) regulatory applications for pipeline candidates.
The Zacks Analyst Blog Highlights ExxonMobil, Coca-Cola, AstraZeneca, CSX and Activision Blizzard
by Zacks Equity Research
ExxonMobil, Coca-Cola, AstraZeneca, CSX and Activision Blizzard are included in this Analyst Blog.
Top Research Reports for Exxon Mobil, Coca-Cola & AstraZeneca
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), The Coca-Cola Company (KO) and AstraZeneca PLC (AZN).
Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down
by Zacks Equity Research
Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.
Apellis' (APLS) Earnings Top, Empaveli Sales Boost Revenues
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) reports better-than-expected results, beating both earnings and revenue estimates. Empaveli sales continue to boost product revenues for the company.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Increases
by Zacks Equity Research
Though Ironwood (IRWD) missed both Q4 earnings and sales estimates, the total prescription demand for the sole-marketed drug Linzess rose 9% year over year.
Ironwood (IRWD) Gets FDA Priority Tag for Linzess sNDA
by Zacks Equity Research
With the FDA granting priority review to Ironwood Pharmaceuticals' (IRWD) sNDA seeking label expansion of Linzess for functional constipation in kids, a decision is expected in the second quarter of 2023.
Pharma Stock Roundup: AZN, ABBV Mixed Q4 Results, BAYRY's New CEO
by Kinjel Shah
AstraZeneca (AZN) and AbbVie (ABBV) report fourth-quarter results. Roche (RHHBY) and J&J (JNJ) announce positive data from studies on pipeline candidates for rare diseases.